Richard T. Piszczatowski

Richard T. Piszczatowski

Auto-generated profile, based on publicly available information

Richard T. Piszczatowski

Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Blood
Verified
Journal Article
Open access
PDF file
RPRichard T. Piszczatowski
Richard T. Piszczatowski
HBHannes E. Bülow
Hannes E. Bülow
USUlrich Steidl
Ulrich Steidl
From signaling mediators in stem cells to markers of differentiation and lineage commitment to facilitators for the entry of viruses, such as HIV-1, cell surface heparan sulfate (HS) glycans with distinct modification patterns play important roles in hematopoietic biology. In this review, we provide an overview of the importance of HS and the proteoglycans (HSPGs) to which they are attached within the major cellular subtypes of the hematopoietic system. We summarize the roles of HSPGs, HS, and HS modifications within each main hematopoietic cell lineage of both myeloid and lymphoid arms. Lastly, we discuss the biological advances in the detection of HS modifications and their potential to further discriminate cell types within hematopoietic tissue.

23 February 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RSRobert F. Stanley
Robert F. Stanley
RPRichard T. Piszczatowski
Richard T. Piszczatowski
BBBoris Bartholdy
Boris Bartholdy
KMKelly Mitchell
Kelly Mitchell
WMWendy M. McKimpson
Wendy M. McKimpson
USUlrich Steidl
Ulrich Steidl
Despite the identification of several oncogenic driver mutations leading to constitutive JAK–STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3−/− MPN mice harbor an expanded Thy1+LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3−/−-induced JAK–STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and Myc. Nol3−/− MPN Thy1+LSK cells share significant molecular similarities with primary CD34+ cells from PMF patients. NOL3 levels are decreased in CD34+ cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies.

6 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RPRichard T. Piszczatowski
Richard T. Piszczatowski
ESEmily Schwenger
Emily Schwenger
SSSriram Sundaravel
Sriram Sundaravel
CSCatarina M. Stein
Catarina M. Stein
YLYang Liu
Yang Liu
USUlrich Steidl
Ulrich Steidl
Cell surfaces display a wide array of molecules that confer identity. While flow cytometry and cluster of differentiation (CD) markers have revolutionized cell characterization and purification, functionally heterogeneous cellular subtypes remain unresolvable by the CD marker system alone. Using hematopoietic lineages as a paradigm, we leverage the extraordinary molecular diversity of heparan sulfate (HS) glycans to establish cellular “glycotypes” by utilizing a panel of anti-HS single-chain variable fragment antibodies (scFvs). Prospective sorting with anti-HS scFvs identifies functionally distinct glycotypes within heterogeneous pools of mouse and human hematopoietic progenitor cells and enables further stratification of immunophenotypically pure megakaryocyte–erythrocyte progenitors. This stratification correlates with expression of a heptad of HS-related genes that is reflective of the HS epitope recognized by specific anti-HS scFvs. While we show that HS glycotyping provides an orthogonal set of tools for resolution of hematopoietic lineages, we anticipate broad utility of this approach in defining and isolating novel, viable cell types across diverse tissues and species.

15 August 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RPRichard T. Piszczatowski
Richard T. Piszczatowski
USUlrich Steidl
Ulrich Steidl
The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function. See related article by Gangat et al., p. 4898

1 July 2026 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
GWGang Wang
Gang Wang
SLSerena Lucotti
Serena Lucotti
LBLinda Bojmar
Linda Bojmar
GTGabriel C. Tobias
Gabriel C. Tobias
RPRichard T. Piszczatowski
Richard T. Piszczatowski
DLDavid Lyden
David Lyden